Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; Regeneron pledges privacy com

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the company faces layoffs and office closure due to financial struggles and a past cyberattack.